$AMGN · Amgen Inc.

Thesis

Modest EPS beat ($4.85 vs $4.76) and revenue ahead on Repatha (+35%) and Tepezza rebound, with biosimilar Stelara (Wezlana) gaining script share faster than modeled. The real swing factor: management likely pulls MariTide Phase 2 obesity readout into H2 2026 vs Street's '2027' marker — a multi-quarter pipeline pull-forward landing into a friendly LLY-fueled sector tape.

What would flip it

MariTide commentary stays cagey or hints at GI tolerability concerns and the obesity premium leaks out of the move.

The market's narrative

Repatha and Tepezza are the growth carriers; biosimilar Stelara (Wezlana) is a debate; obesity/MariTide pipeline is the long-tail call option but most analysts keep readouts at '2027'.

Where the Street may be wrong

• MariTide Phase 2 readout cadence likely tightens to H2 2026 on the call — Street has '2027' modeled — pull-forward is worth ~$20 on PT.
• Wezlana (biosim Stelara) IQVIA scripts +18% WoW in April — share gain running ahead of internal model; ~$1B+ 2026 contributor not in consensus.
• LLY GLP-1 print today (+10%) sets up risk-on biotech bid going into AMGN AH — sector tape is unusually friendly.

Peer read: LLY's blowout Q1 (+56% rev, +125% Mounjaro) creates a halo bid on obesity-pipeline names; AMGN catches part of that flow via MariTide optionality.

Reasoning

• Independent EPS $4.85 vs Street $4.76 (+1.9%); rev $8.68B vs $8.55B (+1.5%) — clean beat with biosimilar upside.
• Repatha (~$650M, +35%) + Tepezza ($520M rebound) carry the top-line; Wezlana (biosim Stelara) is the upside swing factor.
• hype_high (IV30 ~34, short interest 2.1%) BUT framework split applies: forward-pipeline narrative on MariTide is the new-narrative lever (ADP lesson) — not just reported-quarter beat.
• LLY peer halo (+10% today) + sector rotation into defensive pharma pre-print is a +1-2% magnitude amplifier.
• Buy/Hold/Sell 12/16/2 — Hold-heavy mix means upgrades on a clean print are the marginal flow.